HomeCompareTJSCF vs ABBV

TJSCF vs ABBV: Dividend Comparison 2026

TJSCF yields 7.70% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TJSCF wins by $214.16M in total portfolio value
10 years
TJSCF
TJSCF
● Live price
7.70%
Share price
$0.23
Annual div
$0.02
5Y div CAGR
72.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$214.26M
Annual income
$192,886,905.07
Full TJSCF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TJSCF vs ABBV

📍 TJSCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTJSCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TJSCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TJSCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TJSCF
Annual income on $10K today (after 15% tax)
$654.41/yr
After 10yr DRIP, annual income (after tax)
$163,953,869.31/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, TJSCF beats the other by $163,932,813.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TJSCF + ABBV for your $10,000?

TJSCF: 50%ABBV: 50%
100% ABBV50/50100% TJSCF
Portfolio after 10yr
$107.18M
Annual income
$96,455,838.41/yr
Blended yield
89.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TJSCF
No analyst data
Altman Z
1.4
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TJSCF buys
0
ABBV buys
0
No recent congressional trades found for TJSCF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTJSCFABBV
Forward yield7.70%3.06%
Annual dividend / share$0.02$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR72.3%40.6%
Portfolio after 10y$214.26M$102.3K
Annual income after 10y$192,886,905.07$24,771.77
Total dividends collected$212.59M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TJSCF vs ABBV ($10,000, DRIP)

YearTJSCF PortfolioTJSCF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,027$1,326.52$11,550$430.00+$477.00TJSCF
2$15,437$2,568.96$13,472$627.96+$2.0KTJSCF
3$21,828$5,309.95$15,906$926.08+$5.9KTJSCF
4$35,446$12,090.16$19,071$1,382.55+$16.4KTJSCF
5$69,542$31,614.68$23,302$2,095.81+$46.2KTJSCF
6$174,288$99,877.93$29,150$3,237.93+$145.1KTJSCF
7$589,568$403,080.05$37,536$5,121.41+$552.0KTJSCF
8$2,826,471$2,195,632.97$50,079$8,338.38+$2.78MTJSCF
9$19,974,407$16,950,083.38$69,753$14,065.80+$19.90MTJSCF
10$214,259,521$192,886,905.07$102,337$24,771.77+$214.16MTJSCF

TJSCF vs ABBV: Complete Analysis 2026

TJSCFStock

Tianjin Development Holdings Limited, through its subsidiaries, supplies electricity, water, heat, and thermal power to industrial, commercial, and residential customers in the Tianjin Economic and Technological Development Area, the People's Republic of China. It operates through six segments: Utilities, Pharmaceutical, Hotel, Electrical and Mechanical, Port Services, and Elevators and Escalators. The company has an installed transmission capacity of approximately 946,000 kVA; daily water supply capacity of 425,000 tons; and steam transmission pipelines of approximately 462 kilometres, approximately 120 processing stations, and daily distribution capacity of approximately 30,000 tons. It also provides services in relation to construction of electricity supply network, application of technology related to new energy and renewable energy, and electricity construction and related technical services; and offers services in installation and maintenance of water pipes, and technical consultancy, as well as engages in the retail and wholesale of water pipes and related parts. In addition, the company is involved in the manufacture and sale of presses, and mechanical and hydroelectric equipment, as well as large scale pump units. Further, it operates Courtyard by Marriott Hong Kong, a 4-star hotel with 245 guest rooms; researches and develops medicine technology and products; manufactures and sells chemical drugs; designs, manufactures, and prints pharmaceutical packaging products, as well as sells other paper-based packaging materials; manufactures and sells elevators and escalators; operates financing leasing business; and provides port services. The company was incorporated in 1997 and is based in Central, Hong Kong. Tianjin Development Holdings Limited is a subsidiary of Tsinlien Group Company Limited.

Full TJSCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TJSCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TJSCF vs SCHDTJSCF vs JEPITJSCF vs OTJSCF vs KOTJSCF vs MAINTJSCF vs JNJTJSCF vs MRKTJSCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.